Recipharm Reaches Agreement with LobSor Pharmaceuticals
News Sep 10, 2015
Recipharm and LobSor Pharmaceuticals have announced the formation of a manufacturing agreement for LECIGON™.
As part of the agreement, Recipharm will have exclusive manufacturing rights for volumes representing first three years of commercial sales. Recipharm will also support development costs against a mark-up on manufacturing prices, up to a certain volume, when LECIGON is produced for commercial sales.
This agreement is a follow-on to an established collaboration between LobSor and Recipharm for the development and the manufacturing of batches for the recently completed clinical trial.
Carl-Johan Spak, EVP Development & Technology, Recipharm, commented: “We are extremely pleased to have developed our collaborative partnership with LobSor Pharmaceuticals and to have signed an agreement for the future commercial manufacturing of LECIGON, especially as this is a new, innovative drug, which we believe provides a clear benefit to patients with advanced Parkinson’s disease.”
Roger Bolsöy, Managing Director of LobSor Pharmaceuticals said “It is well known that pharmaceutical development is costly and can be cumbersome for a small company. Recipharm is one of our most important strategic partners for the development of our first pharmaceutical product, with whom we have been able to find creative collaboration models to secure the initiation of the LECIGON project. I am impressed that such a large organization as Recipharm has been able to show such entrepreneurial spirit and flexibility to facilitate the development of a company from the early stages through to commercialization”.
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Cocaine Use Alters Gene Expression in Brain Reward CircuitsNews
A study in Biological Psychiatry investigates transcriptome-wide alterations in response to cocaine self-administration in mice.
Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development PartnershipNews
MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018